Ledger.

VC firm blog

OneVentures portfolio

Everything we hold that OneVentures portfolio published.

Articles

The most recent 60 of 61 articles we hold from OneVentures portfolio.

Unnamed stage $34m

Needle-free vaccine innovator banks $34m

A OneVentures post reports a needle-free vaccine developer raising A$34 million; linked items on the page note Eucalyptus's $1.6 billion sale to a US-listed healthcare firm and Vaxxas naming David Peacock chief executive.

Also Blackbird Ventures portfolio·Startup Daily·SmartCompany·Dealroom·SmartCompany·Startup Daily·AFR Technology·Dealroom·Forbes Australia

Under Brandon BioCatalyst portfolio ·leads this story in the feed

News

Blade Therapeutics Updates Enrollment Progress for Phase 2 Study of Lead Investigational Therapy BLD-2660 in Treating Patients with COVID-19 Pneumonia

Blade Therapeutics reports its Phase 2 trial of BLD-2660 in COVID-19 pneumonia has enrolled half its 120-patient goal, with full enrollment expected in the third quarter of 2020.

Exit / M&A

Blade Therapeutics Appoints Accomplished Biopharmaceutical Executive, Mark Timney, as Chairman of the Board

Blade Therapeutics appoints Mark Timney as board chairman, succeeding co-founder Luke Evnin; the release recalls its roughly $90 million raised from investors including OneVentures and The Medicines Company's $9.7 billion sale to Novartis.

2 deals

OneVentures invests in international software company Phocas, bringing business back to Australia and positioning the company for international expansion

OneVentures announces ten million dollars of equity and credit financing for business intelligence firm Phocas, combining a recent credit facility with a 2018 equity investment, as the company prepares for international growth.

Also phocassoftware.com

Series A $20m

Immunology Company Kira Biotech launches with $20M Series A Funding

Brisbane immunology company Kira Biotech has launched with a $20 million Series A, OneVentures leading alongside IP Group and Queensland government support, to progress its lead antibody KB312 into early human studies.

Something wrong? Tell us